Conditioning Regimens Prior to Autologous Transplantation for Multiple Myeloma
A bendamustine-based regimen performed similarly to high-dose melphalan in conditioning prior to autologous stem cell transplantation for multiple myeloma.
Myeloma
Daratumumab Maintenance Shows Clinical Benefit in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
Researchers sought to determine whether daratumumab maintenance therapy would be effective in patients with newly diagnosed multiple myeloma.
Combination Therapy Shows Promise in Patients With Ultra High-Risk Multiple Myeloma, PCL
Researchers sought to determine whether a combination therapy with bortezomib-augmented ASCT would have efficacy in patients with ultra high-risk multiple myeloma or plasma cell leukemia.
FORTE Study Compares Multiple Regimens in Patients With Multiple Myeloma With Cytogenetic Abnormalities
Researchers sought to determine whether a combination carfilzomib-lenalidomide-dexamethasone induction and consolidation with ASCT would improve survival in patients with MM with cytogenetic abnormalities.
Carfilzomib-Based Consolidation Regimen May Be Inferior to ASCT in Patients With Multiple Myeloma
Researchers sought to determine whether carfilzomib-based consolidation and maintenance therapy regimen may yield similar outcomes to those seen with ASCT in patients with MM.
Adding Ixazomib to Dexamethasone Does Not Improve PFS Compared to Pomalidomide in Multiple Myeloma
Researchers sought to determine whether doublet therapy with dexamethasone and ixazomib would improve survival in patients with multiple myeloma compared with pomalidomide.
BCVA Changes and Ocular Symptoms May Aid Belamaf Dosing in Relapsed/Refractory Multiple Myeloma
Researchers sought to determine whether BCVA and ocular symptoms could help determine dosing for belantamab mafodotin in patients with r/r multiple myeloma.
Maintenance With Ixazomib Not Recommended for Patients With Multiple Myeloma Undergoing Allogeneic HCT
Researchers sought to determine whether giving maintenance ixazomib to patients with multiple myeloma who undergo allogeneic hematopoietic stem cell transplantation would have a clinical benefit.
MGTA-145 Plus Plerixafor Effective for Same-Day Hematopoietic Stem Cell Mobilization
Researchers sought to determine whether the combination of MGTA-145 and plerixafor would be effective for HSC mobilization for autologous transplant in patients with multiple myeloma.
Idecabtagene Vicleucel Shows Durable Response in Relapsed/Refractory Multiple Myeloma
Researchers sought to determine whether idecabtagene vicleucel would have durable responses in heavily pretreated patients with relapsed or refractory multiple myeloma.
